
Pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines.
Creyon Bio is a pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines. The company focuses on reimagining drug development from discovery to engineering, utilizing powerful, purpose-built data sets to drive the creation of machine learning models. This enables the engineering of oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety.
Creyon Bio has achieved significant milestones in the field of drug development by leveraging a groundbreaking modular approach. This innovative strategy allows for the efficient and rapid creation of OBMs, positioning the company as a leader in the development of gene-centric therapies. The impact of Creyon Bio's work is evident in its ability to produce safe and effective treatments with a high degree of precision, setting new standards in the pharmaceutical industry.

Cargene
cargene.com

Generate Biomedicines

Avicenna Biosciences

Ordaos
ordaos.bio

Character Biosciences
characterbio.com

Cellarity

Creative BioTherapeutics
creativebio.tech

Cryptyx Bioscience

Octant
octant.bio

Curie.Bio
curie.bio

KreaMedica
kreamedica.com

Cydan
cydanco.com

Owkin
owkin.com

Curi Bio
curibio.com

Acrigen Biosciences
acrigen.com
Companies similar to Creyon Bio include Cargene, Generate Biomedicines, Avicenna Biosciences and Ordaos.
Creyon Bio was founded in 2019.
Creyon Bio's headquarters is located in San Diego, CA, US.
Creyon Bio's most recent funding round was for $40M (USD) in March 2022.
As of Mar 8, 2022, Creyon Bio has raised a total of $40M (USD).
Creyon Bio has 67 employees as of Feb 4, 2024.